General Biological Products Standards
The FDA regulation setting the general standards every licensed biological product must meet: lot-by-lot testing prior to release, the potency, sterility, purity, and identity requirements, mycoplasma testing where applicable, testing of donors for relevant transfusion-transmitted infections (§§610.40–610.41), dating-period limits, and container and package labelling standards. It is the release-testing backbone that sits on top of the biologics CGMP rules.
What this does not cover
stated in the document's own scope- Sets product standards and release testing for licensed biologics; the manufacturing quality system itself is governed by the CGMP regulations (Parts 600–606, 210/211).
- Subpart E's donor-testing requirements serve blood and HCT/P collection; donor eligibility and collection practice are Part 630 and Part 1271 territory.
- Applies to BLA-licensed products; drugs approved under NDAs follow compendial and application specifications rather than Part 610.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 610, "General Biological Products Standards", is the release-testing backbone of US biologics regulation. It requires each lot of a licensed biological product to pass its required tests before release, sets the general standards — potency (by in vitro or in vivo tests designed for the product), sterility, purity, and identity — requires mycoplasma testing for products propagated in cell culture, prescribes donor testing for relevant transfusion-transmitted infections together with donor deferral and HIV/HCV lookback (Subpart E, §§610.40–610.48), limits dating periods, and standardises container and package labelling. Alternative methods are permitted where demonstrated equivalent, which is how modern rapid and molecular methods enter routine biologics release.
Scope & applicability
Licensed biological products under a BLA — vaccines, blood derivatives, and other biologics — and, for the donor-testing subpart, establishments collecting blood and HCT/P donations. It operates alongside Parts 600–606 and the drug CGMP regulations.
Legal basis & how it acquires force
A regulation under the biologics-licensing authority of the Public Health Service Act (section 351) and the FD&C Act, applying to products licensed under a BLA. It has been amended across decades — the donor eligibility final rule of 22 May 2015 rebuilt the §610.40 testing framework around "relevant transfusion-transmitted infections", and 2016 amendments retired obsolete standard-preparation provisions. Compliance is a condition of the biologics licence, alongside the CGMP of Parts 600–606 and 210/211.
Document structure
| Part | Covers |
|---|---|
| Subpart A — Release requirements | Tests prior to release for each lot, and official release procedures where FDA requires samples and protocols |
| Subpart B — General provisions | Potency, sterility, purity, and identity standards, and the equivalency route for alternative methods |
| Subpart D — Mycoplasma | Mycoplasma testing for products grown in cell culture |
| Subpart E — Testing requirements for relevant transfusion-transmitted infections | Donor testing (§610.40), donor deferral (§610.41), and HIV/HCV lookback (§§610.46–610.48) |
| Subpart F — Dating period limitations | Dating periods and the date of manufacture for licensed biologics |
| Subpart G — Labeling standards | Container and package label content for biological products |
Key requirements
- Required tests performed on each lot prior to release, with official release where applicable (Subpart A)
- Potency, sterility, purity, and identity standards for the finished product (Subpart B)
- Mycoplasma testing for products propagated in cell culture
- Donor testing for relevant transfusion-transmitted infections, donor deferral, and HIV/HCV lookback (Subpart E)
- Dating periods and container/package labelling standards (Subparts F–G)
Implementation tips
- Alternative test methods are permitted through the equivalency mechanism — validate and document equivalence rather than assuming the compendial-style named method is mandatory in perpetuity
Revision notes
Amended repeatedly over its long life — notably by the 22 May 2015 donor eligibility final rule (reshaping the §610.40 testing framework around "relevant transfusion-transmitted infections") and 2016 amendments retiring outdated standard-preparation provisions.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 610 supplies the product-standards layer that sits on top of biologics CGMP: Parts 600–606 and the drug CGMP regulations govern how biologics and blood are made, while Part 610 dictates what each lot must demonstrably be before release. Its donor-testing subpart interlocks with the donor-eligibility rules of Part 630 and the blood CGMP of Part 606. The EU reaches equivalent outcomes through marketing-authorisation specifications, Ph. Eur. monographs, and official control authority batch release for vaccines and blood derivatives.
21 CFR Part 610: frequently asked questions
Quick answers to common questions about 21 CFR Part 610.
What are the general standards every licensed biologic must meet?
Each lot must pass its required tests prior to release, and the product must meet the Part 610 standards for potency, sterility, purity, and identity, with mycoplasma testing where the product is grown in cell culture, dating-period limits, and standardised container and package labelling.
Can alternative test methods be used instead of the Part 610 methods?
Yes. The regulation provides an equivalency route: a manufacturer may use methods demonstrated to provide assurances equal to or greater than the specified methods, with the demonstration documented — the pathway by which rapid microbiological and molecular methods replace legacy tests.
What does §610.40 require?
Testing of each donation of human blood and blood components — and donors of HCT/Ps by reference — for relevant transfusion-transmitted infections using licensed, approved, or cleared screening tests, with §610.41 governing deferral of reactive donors and §§610.46–610.48 the HIV and HCV lookback duties.
How does Part 610 relate to Part 606?
Part 606 is the CGMP for blood establishments — how collection and processing operate; Part 610 sets the standards the products and donations must meet, including the Subpart E testing framework. They apply together, with Part 630 supplying the donor-eligibility layer.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.